Disease relevance of BUCRYLATE

• We examined 17 intracranial arteriovenous malformations that were resected after treatment by embolization using bucrylate (isobutyl-2-cyanoacrylate) [1].
• A patient with severe nephrotic syndrome who was too debilitated to undergo surgical nephrectomies, underwent therapeutic bilateral renal artery occlusion by the selective injection of isobutyl 2-cyanoacrylate into the renal arteries [2].
• Treatment of intracerebral arteriovenous malformations with isobutyl 2-cyanoacrylate: initial clinical experience [3].
• Bucrylate (isobutyl 2-cyanoacrylate) was used for the transcatheter embolization of the splenic artery in 4 patients with bleeding gastric varices secondary to splenic vein thrombosis, 3 patients with symptoms of hypersplenism, and 8 patients with bleeding esophageal varices secondary to portal hypertension [4].
• IBCA appears to be an efficient means of occluding the vessels feeding selected primary bone tumors and metastases [5].

High impact information on BUCRYLATE

• Experimental internal iliac artery embolization: evaluation of low viscosity silicone rubber, isobutyl 2-cyanoacrylate, and carbon microspheres [6].
• Herein we describe a new embolic material (isobutyl-2-cyanoacrylate) in 5 cases of renal cancer embolization and in 1 case of bilateral hypogastric embolization for bladder cancer hemorrhage [7].
• Maximum adhesion is obtained with isobutyl 2-cyanoacrylate after 1% acid pretreatment of the dentin [8].
• Recurrent life-threatening hematuria was controlled successfully by transcatheter embolization and infarction of the tumor using a tissue adhesive called isobutyl 2-cyanoacrylate [9].
• Development of sterically stabilized poly(isobutyl 2-cyanoacrylate) nanoparticles by chemical coupling of poly(ethylene glycol) [10].

Chemical compound and disease context of BUCRYLATE

• From November 1976 to September 1979, 46 patients with intracranial arteriovenous malformations or fistulas participated in a clinical study using isobutyl 2-cyanoacrylate (IBCA), with tantalum, for palliative or preoperative occlusion of the blood supply to the abnormalities [3].
• Preliminary angiography and electron microscopy suggest absolute ethyl alcohol is a good neurovascular occlusive agent, and a possible replacement for isobutyl 2-cyanoacrylate in the treatment of angiomas and tumors [11].

Biological context of BUCRYLATE

• An in vivo evaluation of isobutyl 2-cyanoacrylate as an osseous adhesive was done in an effort to answer two questions: Used in limited amounts, can this monomer maintain the reduction of an unstable intra-articular osteochondral fracture while allowing for fracture healing around the sites of adhesive placement [12]?
• A soluble metabolite of isobutyl-2-cyanoacrylate appeared to activate platelet aggregation [13].
• An experimental study was implemented to determine the effectiveness of isobutyl-2-cyanoacrylate (bucrylate) as an oral hemostat, its influence on sequential wound healing, and its potential as a carcinogen [14].

Anatomical context of BUCRYLATE

• Preoperative occlusion of the hepatic artery with isobutyl 2-cyanoacrylate for resection of the "unresectable" hepatic tumor [15].
• The cytotoxicity of methyl- and isobutyl-2-cyanoacrylate adhesives was determined using a rat polymorphonuclear leukocyte suspension [16].
• Under the guidance of intraoperative digital subtraction angiography, isobutyl-2-cyanoacrylate was injected directly into the surgically exposed cavernous sinus [17].
• In one patient, right hemiplegia with aphasia resulted from reflux of IBCA emboli through the artery of the foramen rotundum into the left middle cerebral artery [18].
• The cavernous dural AVM's were treated with polyvinyl-alcohol and/or isobutyl-2-cyanoacrylate (IBCA) embolization of the external carotid artery blood supply [18].

Associations of BUCRYLATE with other chemical compounds

• Contribution of hydroxyapatite to the tensile strength of the isobutyl-2-cyanoacrylate-bone bond [19].
• Treatment of endothelial cells with isobutyl-2-cyanoacrylate and 1-carboxyheptylimidazole did not significantly alter the amount of platelet aggregation [13].
• Thoracic duct embolization was created by injecting an isobutyl 2-cyanoacrylate/iophendylate (IBCA) mixture through a cannulated mesenteric lymphatic vessel in eight normal dogs [20].
• Physical properties of ethyl 2-cyanoacrylate (Aron Alpha) were studied in comparison with isobutyl 2-cyanoacrylate (IBCA) [21].

Gene context of BUCRYLATE

• Intravascular use of isobutyl 2-cyanoacrylate: Part 2 Treatment of carotid-cavernous fistulas [22].

Analytical, diagnostic and therapeutic context of BUCRYLATE

• The angiographic, morphologic, and histologic effects of carbon microspheres, isobutyl 2-cyanoacrylate (IBC), and low viscosity silicone rubber (LVSR) were compared [6].
• A comparison of isobutyl 2-cyanoacrylate glue, fibrin adhesive, and oxidized regenerated cellulose for control of needle hole bleeding from polytetrafluoroethylene vascular prostheses [23].
• There is controversy as to the possible toxic effects of isobutyl-2-cyanoacrylate (bucrylate) when this substance is used for purposes of therapeutic embolization [24].
• This technique could extend the benefits of transthoracic needle biopsy to mechanically ventilated patients, but further studies to prove the safety of isobutyl 2-cyanoacrylate are necessary [25].
• Evaluation by plain film, CT, and cerebral angiography of the isobutyl-2-cyanoacrylate deposits showed that when the polymer was positioned predominantly in arterial feeders there was invariably reconstitution of the AVM nidus through leptomeningeal, deep medullary, and/or dural collaterals [26].

References